DFTX

Definium Therapeutics, Inc.

NASDAQ: DFTX · HEALTHCARE · BIOTECHNOLOGY

$33.00

-4.26% today

Updated 2026-11-12

Market cap

$4.36B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.43

Dividend yield

—

52W range

$10 – $50

Volume

2.1M

Market cap

$4.36B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.43

Dividend yield

—

52W range

$10 – $50

Volume

2.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-0.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →259 stocks currently score above 75

Price targets

Analyst target

$72.56

+119.88%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

4 Strong Buy14 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.04x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -0.38 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-52.78M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-56.80M	$-95.73M	$-108.68M	$-183.79M	$-158.99M
EPS	—	—	—	—	$-3.43
Free cash flow	$-50.14M	$-64.36M	$-79.13M	$-131.56M	$-52.78M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DFTX	$4.36B	25	4.3	3.0	5.0	6.5	—	Avoid
LLY	$1.26T	74	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$657.68B	54	4.7	8.5	3.7	5.5	—	Buy
ABBV	$521.11B	77	6.7	9.0	4.0	5.0	-85.21%	Strong Buy
MRK	$368.89B	44	3.3	6.5	2.0	5.0	-72.89%	Hold
UNH	$365.29B	62	6.7	6.0	4.7	5.5	-20.81%	Buy

Smart narrative

Definium Therapeutics, Inc. trades at $33.00. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.38, it sits in the distress.

Frequently asked questions

What is Definium Therapeutics, Inc.'s stock price?

Definium Therapeutics, Inc. (DFTX) trades at $33.00.

Is Definium Therapeutics, Inc. overvalued?

Definium Therapeutics, Inc. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Definium Therapeutics, Inc. (DFTX)?

The 12-month analyst consensus target is $72.56, about 119.9% above the current $33.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Definium Therapeutics, Inc.'s Altman Z-Score is -0.38, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-85.19%

Beta2.21

50D MA$37.77

200D MA$29.60

Shares out0.13B

Float0.13B

Short ratio—

Avg volume2.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DFTX vs LLY →DFTX vs JNJ →DFTX vs ABBV →Stock screener →